CHRS - Coherus BioSciences Inc logo

CHRS

Coherus BioSciences Inc

Coherus BioSciences develops and commercializes biosimilars and immunotherapies for cancer treatment. Its key products include UDENYCA, LOQTORZI, and investigational monoclonal antibodies, targeting various oncological conditions in the U.S. market.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$40today

Score Overview

1 Year
Score
Net Growth23.10%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth20.78%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score5.0
Net Growth54.39%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-84.40%
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-2.84%
Net Trend60%
Net Income Consistency
Rev Growth-73.21%
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth-50.30%
Net Trend58%
Net Income Consistency
Rev Growth63.75%
Rev Trend50%
Revenue Consistency

See the full market ranking โ†’

Coherus BioSciences Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 475M to $ 42M and net income went from $ 132M to -$ 170M. Revenue increased in 3 of those 5 years; net income in 3.

Across Coherus BioSciences Inc's full reported history, from 2014 to 2025, revenue grew from $ 31M to $ 42M and net income went from -$ 87M to -$ 170M. Revenue increased in 50% of the years measured; net income in 58%.

Coherus BioSciences Inc currently holds a 5-year HDB Score of 5.0 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.17โ€”
1 Year2025-08-12
$ 0.9227.74%
5 Years2021-08-12
$ 13.63-91.42%
10 Years2016-08-12
$ 29.50-96.03%
All Time2014-11-06
$ 12.61-90.72%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 50M-$ 130M$ 105M
2025$ 42M-$ 170M$ 172M
2024$ 266M$ 28M$ 125M
2023$ 257M-$ 237M$ 117M
2022$ 211M-$ 291M$ 191M
2021$ 326M-$ 287M$ 417M
2020$ 475M$ 132M$ 541M
2019$ 356M$ 89M$ 177M
2018$ 1M-$ 209M$ 72M
2017$ 1M-$ 238M$ 126M
2016$ 190M-$ 127M$ 124M
2015$ 30M-$ 223M$ 158M
IPO2014$ 31M-$ 87M$ 150M

Explore beyond CHRS

You're looking at Coherus BioSciences Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies